4/A: AVNS CEO Pacitti Amends Stock Option Grant Details

AVANOS MEDICAL, INC. CEO David Pacitti filed an amended Form 4 to correct an error in the calculation of stock options and restricted share units awarded on March 13, 2026.

Summary

• CEO David Pacitti received an award of 101,341 time-based restricted share units (TRSUs) on March 13, 2026, under the company's 2021 Long Term Incentive Plan.
• These TRSUs will vest in three tranches: 1/3 on March 13, 2027, 1/3 on March 13, 2028, and 1/3 on March 13, 2029.
• Pacitti also received 241,021 employee stock options with an exercise price of $13.69 on March 13, 2026.
• The stock options will vest as follows: 30% on March 13, 2027, 30% on March 13, 2028, and 40% on March 13, 2029, and expire on March 13, 2036.
• The filing is an amendment (Form 4/A) to correct an error in the initial calculation of the number of stock options issued to the CEO on March 13, 2026.
• Following these transactions, Pacitti beneficially owns 343,388 shares of common stock and 241,021 employee stock options.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it confirms a significant long-term equity award for the CEO, aligning his incentives with shareholder value, despite the minor administrative correction.

Positives

• The CEO received a significant equity award (101,341 TRSUs and 241,021 stock options), aligning his interests with long-term shareholder value.
• The awards are part of the company's 2021 Long Term Incentive Plan, indicating a structured approach to executive compensation.

Negatives

• An error in the initial calculation of stock options required an amendment, which could suggest administrative oversight, though it was promptly corrected.

Risks

• No specific risks are mentioned in this Form 4/A filing beyond the general risk associated with equity compensation, such as stock price fluctuation impacting the value of the awards.

Future Outlook

The vesting schedules for the restricted share units and stock options extend through March 13, 2029, indicating a long-term incentive structure for the CEO tied to future company performance and share price appreciation.

Management Comments

• This Form 4/A is being filed to correct an error in the calculation of the number of stock options issued to the Reporting Person on March 13, 2026 pursuant to the Issuer's 2021 Long-Term Incentive Plan, as amended.

Industry Context

StockSavvy.ai notes that equity compensation, including restricted stock units and stock options, is a standard practice across industries, particularly in the medical technology sector, to incentivize executive performance and align management interests with shareholder returns. The specific vesting schedule is typical for long-term incentive plans.

Comparison to Industry Standards

• Equity awards of this nature and size for a CEO of a company like AVANOS MEDICAL, INC. are generally in line with compensation practices observed in the broader medical device and healthcare technology industry.
• Similar long-term incentive structures are common at companies such as Medtronic (MDT) or Stryker (SYK), where executive compensation packages often include a significant equity component with multi-year vesting periods to promote sustained performance and retention.

Stakeholder Impact

• Shareholders: The equity awards align the CEO's long-term interests with shareholder value creation, potentially leading to more focused strategic decisions aimed at increasing stock price.
• Employees: The long-term incentive plan for the CEO may signal the company's commitment to performance-based compensation, potentially influencing broader employee incentive structures.

Next Steps

• Vesting of 1/3 of TRSUs and 30% of stock options on March 13, 2027.
• Vesting of 1/3 of TRSUs and 30% of stock options on March 13, 2028.
• Vesting of 1/3 of TRSUs and 40% of stock options on March 13, 2029.
• Expiration of employee stock options on March 13, 2036.

Key Dates

Recommendation

This filing is an administrative correction to an executive's equity compensation, not a new material event. While the awards themselves are a positive for aligning management incentives, the amendment itself does not provide new information warranting a change in investment thesis. Investors should hold and monitor the company's operational performance and broader market conditions.

Keywords

AVANOS MEDICAL, AVNS, David Pacitti, CEO, Stock Options, Restricted Share Units, Equity Compensation, SEC Form 4/A, Insider Trading, Long Term Incentive Plan